In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Cytotoxic Drug market for 2018-2023.
Cytotoxic drugs inhibit or prevent the function of cells. Cytotoxic drugs are primarily used to treat cancer, frequently as part of a chemotherapy regime. Recently, their uses have expanded to treat certain skin conditions (e.g., psoriasis), rheumatoid and juvenile rheumatoid arthritis, and steroid-resistant muscle conditions. The most common forms of cytotoxic drugs are known as antineoplastic. The terms antineoplastic and cytotoxic are often used interchangeably.
The classification of Cytotoxic Drug includes Injection, Solid Oral Dose Forms and others, and the proportion of Injection in 2016 is about 94%, and the proportion is in decreasing trend from 2012 to 2016.
Cytotoxic Drug is widely used in Breast Cancer, Blood Cancer, Prostate Cancer, Respiratory/Lung Cancer and other diseases. The most proportion of Cytotoxic Drug is for other diseases, and the consumption proportion for blood cancer in 2016 is about 24%.
Market competition is intense. Roche, Eli Lilly, Celgene, Sanofi, eisai, Sumitomo Dainippon Pharma, Merck, Seattle Genetics, Takeda, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
Over the next five years, LPI(LP Information) projects that Cytotoxic Drug will register a 1.1% CAGR in terms of revenue, reach US$ 14900 million by 2023, from US$ 13900 million in 2017.
This report presents a comprehensive overview, market shares, and growth opportunities of Cytotoxic Drug market by product type, application, key manufacturers and key regions.
To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:
Segmentation by product type:
Solid Oral Dose Forms
Segmentation by application:
This report also splits the market by region:
Middle East & Africa
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Sumitomo Dainippon Pharma
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
To study and analyze the global Cytotoxic Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
To understand the structure of Cytotoxic Drug market by identifying its various subsegments.
Focuses on the key global Cytotoxic Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Cytotoxic Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Cytotoxic Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.